Meta-analysis of efficacy and safety of cabozantinib in the treatment of advanced thyroid cancer

ZHU Jing; XIE Ji; ZHAO Ziting; HU Xiaoxia

doi:10.6039/j.issn.1001-0408.2023.22.20

您当前的位置：

首页 >

文章列表页 >

Meta-analysis of efficacy and safety of cabozantinib in the treatment of advanced thyroid cancer

更新时间：2023-11-25

- Meta-analysis of efficacy and safety of cabozantinib in the treatment of advanced thyroid cancer
- ZHONGGUO YAOFANG Vol. 34, Issue 22, Pages: 2800-2804(2023)
- 作者机构：
  
  1.兰州大学第二医院老年病科，兰州　730030
  2.兰州大学第二医院肿瘤内科，兰州　730030
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.22.20
  CLC： R979.1;R581.9
- Published：30 November 2023，
  
  Received：03 April 2023，
  
  Revised：19 October 2023，
扫描看全文
竺晶,谢骥,赵紫婷等.卡博替尼治疗晚期甲状腺癌有效性和安全性的Meta分析[J].中国药房,2023,34(22):2800-2804.

ZHU Jing,XIE Ji,ZHAO Ziting,et al.Meta-analysis of efficacy and safety of cabozantinib in the treatment of advanced thyroid cancer[J].ZHONGGUO YAOFANG,2023,34(22):2800-2804.
竺晶,谢骥,赵紫婷等.卡博替尼治疗晚期甲状腺癌有效性和安全性的Meta分析[J].中国药房,2023,34(22):2800-2804. DOI： 10.6039/j.issn.1001-0408.2023.22.20.

ZHU Jing,XIE Ji,ZHAO Ziting,et al.Meta-analysis of efficacy and safety of cabozantinib in the treatment of advanced thyroid cancer[J].ZHONGGUO YAOFANG,2023,34(22):2800-2804. DOI： 10.6039/j.issn.1001-0408.2023.22.20.

摘要

目的

评价卡博替尼治疗晚期甲状腺癌的有效性和安全性。

方法

计算机检索PubMed、the Cochrane Library、Embase、ClinicalTrials.gov、万方数据、维普网、中国知网、中国临床试验注册中心，收集卡博替尼（试验组）对比安慰剂（对照组）的随机对照试验（RCT），检索时限均为建库至2022年11月。筛选文献、提取资料及质量评价后，采用RevMan 5.4软件进行Meta分析。

结果

共纳入4项RCT，共计588例患者。Meta分析结果显示，试验组患者的无进展生存期（PFS）[HR＝0.24，95%CI（0.19，0.31），

＜0.000 01]、客观缓解率（ORR）[RR＝31.46，95%CI（6.32，156.75），

＜0.000 1]、3～4级不良事件（AE）[RR＝2.15，95%CI（1.76，2.61），

＜0.000 01]、严重不良事件[RR＝1.78，95%CI（1.11，2.83），

＝0.02]、腹泻[RR＝3.29，95%CI（1.62，6.66），

＝0.001]、掌跖红斑感觉异常[RR＝28.19，95%CI（12.25，64.88），

＜0.000 01]、高血压[RR＝6.50，95%CI（3.90，10.83），

＜0.000 01]发生率均显著高于对照组，而两组患者的总生存期（OS）[HR＝0.83，95%CI（0.67，1.02），

＝0.07]、疲劳发生率[RR＝1.25，95%CI（0.78，1.98），

＝0.35]比较差异均无统计学意义。按不同肿瘤类型进行亚组分析结果显示，试验组分化型甲状腺癌、甲状腺髓样癌患者的PFS、ORR均显著高于对照组（

＜0.05），其OS与对照组比较差异均无统计学意义（

＞0.05）。

结论

卡博替尼可延长晚期甲状腺癌患者的PFS，增加ORR，但AE发生率较高。

Abstract

OBJECTIVE

To review the efficacy and safety of cabozantinib in the treatment of advanced thyroid cancer.

METHODS

Retrieved from PubMed， the Cochrane Library， Embase， ClinicalTrials.gov， Wanfang data， VIP， CNKI and China Clinical Trials Registry， randomized controlled trials （RCTs） about cabozantinib （trial group） versus placebo （control group） were collected from the inception to Nov. 2022. After literature screening， data extraction and quality evaluation， meta-analysis was performed by using RevMan 5.4 software.

RESULTS

A total of 4 RCTs were included involving 588 patients. The results of the meta-analysis showed that the progression free survival （PFS） [HR＝0.24， 95%CI （0.19，0.31），

＜0.000 01]， objective response rate （ORR） [RR＝31.46， 95%CI （6.32，156.75），

＜0.000 1]， the incidence of grade 3-4 adverse event （AE） [RR＝2.15，95%CI （1.76，2.61），

＜0.000 01]， severe adverse event [RR＝1.78，95%CI （1.11，2.83），

＝0.02]， diarrhea [RR＝3.29，95%CI（1.62，6.66），

＝0.001]， palmar-plantar erythrodysesthesia syndrome [RR＝28.19，95%CI （12.25，64.88），

＜0.000 01]， and hypertension [RR＝6.50，95%CI （3.90，10.83），

＜0.000 01] in trial group were significantly higher than control group； there was no statistical significance in overall survival （OS） [HR＝0.83，95%CI （0.67，1.02），

＝0.07] or the incidence of fatigue [RR＝1.25，95%CI （0.78，1.98），

＝0.35] between the two groups. Subgroup analysis showed that PFS and ORR in patients with differentiated thyroid carcinoma （DTC） and medullary thyroid carcinoma （MTC） in the trial group were significantly higher than control group （

＜0.05）. There was no significant difference in OS of DTC and MTC patients in the trial group compared with the control group （

＞0.05）.

CONCLUSIONS

Cabozantinib can prolong PFS and increase ORR in patients with advanced thyroid cancer， but the incidence of AE is high.

关键词

卡博替尼甲状腺癌有效性安全性Meta分析

Keywords

thyroid cancerefficacysafetymeta-analysis

references

DENG Y J，LI H T，WANG M，et al. Global burden of thyroid cancer from 1990 to 2017[J]. JAMA Netw Open，2020，3（6）：e208759.

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.

MIRANDA-FILHO A，LORTET-TIEULENT J，BRAY F，et al. Thyroid cancer incidence trends by histology in 25 countries：a population-based study[J]. Lancet Diabetes Endocrinol，2021，9（4）：225-234.

ANCKER O V，KRÜGER M，WEHLAND M，et al. Multikinase inhibitor treatment in thyroid cancer[J]. Int J Mol Sci，2019，21（1）：10.

LAHA D，NILUBOL N，BOUFRAQECH M. New therapies for advanced thyroid cancer[J]. Front Endocrinol，2020，11：82.

中国医师协会外科医师分会甲状腺外科医师委员会，中国研究型医院学会甲状腺疾病专业委员会. 分化型甲状腺癌术后管理中国专家共识（2020版）[J].中国实用外科杂志，2020，40（9）：1021-1028.

Chinese Thyroid Association，Chinese Collage of Surgeons，Chinese Medical Doctor Association，Chinese Research Hospital Association Thyroid Disease Committee. Expert consensus on postoperative management of dif-ferentiated thyroid cancer（2020 edition）[J].Chin J Pract Surg，2020，40（9）：1021-1028.

CABANILLAS M E，RYDER M，JIMENEZ C. Targeted therapy for advanced thyroid cancer：kinase inhibitors and beyond[J]. Endocr Rev，2019，40（6）：1573-1604.

EFSTATHIADOU Z A，TSENTIDIS C，BARGIOTA A，et al. Benefits and limitations of TKIs in patients with medullary thyroid cancer：a systematic review and meta-analysis[J]. Eur Hyroid J，2021，10（2）：125-139.

DUKE E S，BARONE A K，CHATTERJEE S，et al. FDA approval summary：cabozantinib for differentiated thyroid cancer[J]. Clin Cancer Res，2022，28（19）：4173-4177.

HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials[J]. BMJ，2011，343：d5928.

BROSE M S，ROBINSON B，SHERMAN S I，et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer（COSMIC-311）：a randomised，double-blind，placebo-controlled，phase 3 trial[J]. Lancet Oncol，2021，22（8）：1126-1138.

BROSE M S，ROBINSON B G，SHERMAN S I，et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer：updated results from the phase 3 COSMIC-311 trial[J]. Cancer，2022，128（24）：4203-4212.

ELISEI R，SCHLUMBERGER M J，MÜLLER S P，et al. Cabozantinib in progressive medullary thyroid cancer[J]. J Clin Oncol，2013，31（29）：3639-3646.

SCHLUMBERGER M，ELISEI R，MÜLLER S，et al. Overall survival analysis of EXAM，a phase Ⅲ trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma[J]. Ann Oncol，2017，28（11）：2813-2819.

中国抗癌协会甲状腺癌专业委员会，中国抗癌协会头颈肿瘤专业委员会，中华医学会肿瘤学分会甲状腺肿瘤专业委员会，等. 晚期甲状腺癌靶向药物应用中国专家共识：2022年版[J]. 中华普通外科杂志，2022，37（12）：881-889.

Thyroid Cancer Professional Committee of Chinese Anti-Cancer Association，Head and Neck Cancer Professional Committee of Chinese Anti-cancer Association，Thyroid Cancer Professional Committee of Oncology Branch of Chinese Medical Association，et al. China expert consensus on the application of targeted drugs for advanced thyroid cancer：2022 edition[J]. Chin J Gen Surg，2022，37（12）：881-889.

MARKOWITZ J N，FANCHER K M. Cabozantinib：a multitargeted oral tyrosine kinase inhibitor[J]. Pharmacotherapy，2018，38（3）：357-369.

SALTIKI K，SIMEAKIS G，KARAPANOU O，et al. Mana-gement of endocrine disease：medullary thyroid cancer：from molecular biology and therapeutic pitfalls to future targeted treatment perspectives[J]. Eur J Endocrinol，2022，187（3）：R53-R63.

BROSE M S，NUTTING C M，JARZAB B，et al. Sorafenib in radioactive iodine-refractory，locally advanced or metastatic differentiated thyroid cancer：a randomised，double-blind，phase 3 trial[J]. Lancet，2014，384（9940）：319-328.

SCHLUMBERGER M，TAHARA M，WIRTH L J，et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med，2015，372（7）：621-630.

KOEHLER V F，ADAM P，FRANK-RAUE K，et al. Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer[J]. Thyroid，2021，31（3）：459-469.

韩俊伟，李元平，程瑶，等. 血管内皮生长因子受体酪氨酸激酶抑制剂致肿瘤患者发生严重胃肠道事件风险的网状meta分析[J]. 药物不良反应杂志，2022，24（3）：130-138.

HAN J W，LI Y P，CHENG Y，et al. Risk of severe gastrointestinal events in patients with cancer caused by vascular endothelial growth factor receptor tyrosine kinase inhibitors：a network meta-analysis[J]. Adverse Drug React J，2022，24（3）：130-138.

KLEIN HESSELINK E N，STEENVOORDEN D，KAPITEIJN E，et al. Therapy of endocrine disease： response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma：a systematic review and meta-analysis[J]. Eur J Endocrinol，2015，172（5）：R215-R225.

TSANG V H M. Management of treatment-related toxicities in advanced medullary thyroid cancer[J]. Curr Opin Oncol，2019，31（3）：236-242.

WIRTH L J，TAHARA M，ROBINSON B，et al. Treatment-emergent hypertension and efficacy in the phase 3 study of （E7080） lenvatinib in differentiated cancer of the thyroid（SELECT）[J]. Cancer，2018，124（11）：2365-2372.

ENOKIDA T，TAHARA M. Management of VEGFR-targeted TKI for thyroid cancer[J]. Cancers，2021，13（21）：5536.

BROSE M S，SMIT J，LIN C C，et al. Timing of multikinase inhibitor initiation in differentiated thyroid cancer[J]. Endocr Relat Cancer，2017，24（5）：237-242.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Meta-analysis of efficacy and safety of belimumab in the treatment of childhood-onset systemic lupus erythematosus

Efficacy and safety of new oral anticoagulants in patients with nonvalvular atrial fibrillation after left atrial appendage occlusion：a meta-analysis

Efficacy and safety of low-dose hydrocortisone for the prevention and treatment of bronchopulmonary dysplasia in very premature infants： a meta-analysis

Efficacy and safety of tenecteplase in the treatment of acute ischemic stroke： a meta-analysis

Efficacy and safety of bimatoprost versus latanoprost in the treatment of glaucoma：a meta-analysis

Related Author

YU Xin

ZHAI Wensheng

ZHANG Mengmeng

REN Xiangge

YU Qiaoling

ZHAI Weiwei

LIU Ping

QIU Bo

Related Institution

School of Pediatric Medicine， Henan University of Traditional Chinese Medicine

First Districts of Pediatrics， the First Affiliated Hospital of Henan University of Chinese Medicine

Graduate School of Hebei Medical University

Dept. of Pharmacy， Hebei General Hospital

Dept. of Neonatology， Haikou Maternal and Child Health Hospital

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰